Table 2.

Laboratory data on admission and treatments during hospitalization.

Laboratory data on admission
WBC count (/μL)	6040 (4325–8115)	5360 (3720–7080)	5750 (3925–7965)	7600 (6050–11,060)	< 0.0001*
Neutrophil count (/μL)	4603 (2852–6331)	3692 (2422–5411)	4070 (2604–5789)	6445 (4956–9665)	< 0.0001*
Lymphocyte count (/μL)	834 (579–1109)	1026 (789–1527)	788 (623–934)	612 (270–809)	< 0.0001*
Platelet count (× 1000/μL)	188 (142–243)	193 (151–247)	165 (123–217)	208 (152–270)	0.048*
Hemoglobin (g/dL)	13.6 (12.0–15.0)	14 (13.2–15.4)	13.6 (11.5–17.8)	13.1 (11.7–14.8)	0.050*
D-dimer (μg/mL)	1.2 (1.0–1.6)	1.06 (0.86–1.41)	1.27 (1.04–2.06)	1.24 (1.15–1.47)	0.014*
CRP (mg/dL)	4.1 (0.9–9.3)	1.3 (0.3–4.5)	5.6 (1.7–10.8)	8.7 (4.2–15.4)	< 0.0001*
Total bilirubin (mg/dL)	0.5 (0.4–0.8)	0.5 (0.3–0.8)	0.7 (0.4–0.8)	0.5 (0.4–0.7)	0.305
Creatinine (mg/dL)	0.82 (0.64–1.17)	0.78 (0.61–0.91)	0.94 (0.63–1.50)	0.82 (0.68–1.70)	0.141
Received treatment (percent [number])
Mechanical ventilation use	28.7 [39]	0.0 [0]	6.8 [3]	97.3 [36]	< 0.0001*
High-FLOW Nasal Oxygenation use	0.7 [1]	0.0 [0]	0.0 [0]	2.7 [1]	0.270
Systemic steroids	58.1 [79]	27.3 [15]	72.7 [32]	86.5 [32]	< 0.0001*
Ciclesonide	56.6 [77]	52.7 [29]	50.0 [22]	70.3 [26]	0.140
Remdesivir	34.6 [47]	3.6 [2]	43.2 [19]	70.3 [26]	< 0.0001*
Favipiravir	27.2 [37]	7.3 [4]	36.4 [16]	45.9 [17]	< 0.0001*
Tocilizumab	5.9 [8]	0.0 [0]	0.0 [0]	21.6 [8]	< 0.0001*
Chlorquine	12.5 [17]	16.4 [9]	6.8 [3]	13.5 [5]	0.353

*p < 0.05.